{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T10:37:48Z","timestamp":1718620668471},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,3,27]],"date-time":"2013-03-27T00:00:00Z","timestamp":1364342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s00280-013-2147-4","type":"journal-article","created":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T07:49:34Z","timestamp":1364284174000},"page":"1485-1491","source":"Crossref","is-referenced-by-count":9,"title":["Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer"],"prefix":"10.1007","volume":"71","author":[{"given":"Davendra P. S.","family":"Sohal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Metz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce J.","family":"Giantonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Plastaras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Kochman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursina R.","family":"Teitelbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Harlacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel F.","family":"Heitjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Drebin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"O\u2019Dwyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,27]]},"reference":[{"issue":"1","key":"2147_CR1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, Naishadham D, Jemal A (2012) Cancer statistics 2012 CA. Cancer J clin 62(1):10\u201329. doi: 10.3322\/caac.20138","journal-title":"Cancer J clin"},{"key":"2147_CR2","volume-title":"AJCC cancer staging manual","author":"AJCC","year":"2010","unstructured":"AJCC (2010) AJCC cancer staging manual, 7th edn. Springer, New York","edition":"7"},{"issue":"4","key":"2147_CR3","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/cncr.22852","volume":"110","author":"KY Bilimoria","year":"2007","unstructured":"Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP, Talamonti MS (2007) Validation of the 6th edition AJCC pancreatic cancer staging system: report from the national cancer database. Cancer 110(4):738\u2013744. doi: 10.1002\/cncr.22852","journal-title":"Cancer"},{"key":"2147_CR4","unstructured":"Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson III AB, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella II P, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM (2012) NCCN Guidelines: Pancreatic Adenocarcinoma."},{"issue":"1\u20133","key":"2147_CR5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF02924235","volume":"7","author":"JL Weese","year":"1990","unstructured":"Weese JL, Nussbaum ML, Paul AR, Engstrom PF, Solin LJ, Kowalyshyn MJ, Hoffman JP (1990) Increased resectability of locally advanced pancreatic and periampullary carcinoma with neoadjuvant chemoradiotherapy. Int J Pancreatol: Off J Int Assoc Pancreatol 7(1\u20133):177\u2013185","journal-title":"Int J Pancreatol: Off J Int Assoc Pancreatol"},{"issue":"1","key":"2147_CR6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.1998.16.1.317","volume":"16","author":"JP Hoffman","year":"1998","unstructured":"Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB 3rd (1998) Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an eastern cooperative oncology group study. J Clin Oncol: Off J Am Soc Clin Oncol 16(1):317\u2013323","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"10","key":"2147_CR7","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1586\/era.11.125","volume":"11","author":"SM Kircher","year":"2011","unstructured":"Kircher SM, Krantz SB, Nimeiri HS, Mulcahy MF, Munshi HG, Benson AB 3rd (2011) Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients. Expert Rev Anticancer Ther 11(10):1555\u20131565. doi: 10.1586\/era.11.125","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2 Suppl 5","key":"2147_CR8","first-page":"13","volume":"25","author":"JM Extra","year":"1998","unstructured":"Extra JM, Marty M, Brienza S, Misset JL (1998) Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25(2 Suppl 5):13\u201322","journal-title":"Semin Oncol"},{"issue":"15","key":"2147_CR9","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2005.06.023","volume":"23","author":"C Louvet","year":"2005","unstructured":"Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, Zaniboni A, Ducreux M, Aitini E, Taieb J, Faroux R, Lepere C, de Gramont A (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol: Off J Am Soc Clin Oncol 23(15):3509\u20133516. doi: 10.1200\/jco.2005.06.023","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"7","key":"2147_CR10","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2007.12.8223","volume":"26","author":"L Moureau-Zabotto","year":"2008","unstructured":"Moureau-Zabotto L, Phelip JM, Afchain P, Mineur L, Andre T, Vendrely V, Lledo G, Dupuis O, Huguet F, Touboul E, Balosso J, Louvet C (2008) Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2\u00a0months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study. J Clin Oncol: off J Am Soc Clin Oncol 26(7):1080\u20131085. doi: 10.1200\/jco.2007.12.8223","journal-title":"J Clin Oncol: off J Am Soc Clin Oncol"},{"issue":"1","key":"2147_CR11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/ncponc0026","volume":"1","author":"DJ Kerr","year":"2004","unstructured":"Kerr DJ (2004) Targeting angiogenesis in cancer: clinical development of bevacizumab. Nat Clin Pract Oncol 1(1):39\u201343. doi: 10.1038\/ncponc0026","journal-title":"Nat Clin Pract Oncol"},{"issue":"31","key":"2147_CR12","doi-asserted-by":"crossref","first-page":"8033","DOI":"10.1200\/JCO.2005.01.9661","volume":"23","author":"HL Kindler","year":"2005","unstructured":"Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM, Vokes EE (2005) Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol: Off J Am Soc Clin Oncol 23(31):8033\u20138040. doi: 10.1200\/JCO.2005.01.9661","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"23","key":"2147_CR13","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 350(23):2335\u20132342. doi: 10.1056\/NEJMoa032691","journal-title":"New Engl J Med"},{"issue":"26","key":"2147_CR14","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New Engl J Med 357(26):2666\u20132676. doi: 10.1056\/NEJMoa072113","journal-title":"New Engl J Med"},{"key":"2147_CR15","doi-asserted-by":"crossref","unstructured":"Wilson VC, Claghorn K, Guo M, Hampshire M, O\u2019Dwyer P, Sun W, Drebin J, Rosato E, Whittington R, Metz JM (2007) Aggressive supportive care improves outcomes in the combined modality treatment of pancreatic and Duodenal cancer. Int J Radiat Oncol Biol Phys 69 (3 Suppl): Abstr 2139","DOI":"10.1016\/j.ijrobp.2007.07.1309"},{"issue":"22","key":"2147_CR16","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1200\/JCO.2010.33.8038","volume":"29","author":"CH Crane","year":"2011","unstructured":"Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, Haque W, Hobbs BD, Krishnan S, Fleming JB, Das P, Lee JE, Abbruzzese JL, Wolff RA (2011) Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol: Off J Am Soc Clin Oncol 29(22):3037\u20133043. doi: 10.1200\/JCO.2010.33.8038","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"12","key":"2147_CR17","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1002\/cncr.25742","volume":"117","author":"HJ Mamon","year":"2011","unstructured":"Mamon HJ, Niedzwiecki D, Hollis D, Tan BR, Mayer RJ, Tepper JE, Goldberg RM, Blackstock AW, Fuchs CS (2011) A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003. Cancer 117(12):2620\u20132628. doi: 10.1002\/cncr.25742","journal-title":"Cancer"},{"issue":"12","key":"2147_CR18","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","volume":"25","author":"BJ Giantonio","year":"2007","unstructured":"Giantonio BJ, Catalano PJ, Meropol NJ, O\u2019Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol: Off J Am Soc Clin Oncol 25(12):1539\u20131544. doi: 10.1200\/JCO.2006.09.6305","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"4","key":"2147_CR19","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa1111097","volume":"366","author":"HD Bear","year":"2012","unstructured":"Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N (2012) Bevacizumab added to neoadjuvant chemotherapy for breast cancer. New Engl J Med 366(4):310\u2013320. doi: 10.1056\/NEJMoa1111097","journal-title":"New Engl J Med"},{"issue":"8","key":"2147_CR20","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","volume":"27","author":"M Reck","year":"2009","unstructured":"Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: aVAil. J Clin Oncol: Off J Am Soc Clin Oncol 27(8):1227\u20131234. doi: 10.1200\/JCO.2007.14.5466","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"4","key":"2147_CR21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa1111065","volume":"366","author":"G Minckwitz von","year":"2012","unstructured":"von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Muller BM, Denkert C, Loibl S, Nekljudova V, Untch M (2012) Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. New Engl J Med 366(4):299\u2013309. doi: 10.1056\/NEJMoa1111065","journal-title":"New Engl J Med"},{"issue":"7","key":"2147_CR22","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2005.03.6780","volume":"24","author":"CH Crane","year":"2006","unstructured":"Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters PW, Charnsangavej C, Delclos ME, O\u2019Reilly M, Lee JE, Wolff RA (2006) Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol: Off J Am Soc Clin Oncol 24(7):1145\u20131151. doi: 10.1200\/JCO.2005.03.6780","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"13","key":"2147_CR23","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1200\/JCO.2008.20.0238","volume":"27","author":"E Cutsem Van","year":"2009","unstructured":"Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, Moore MJ (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol: Off J Am Soc Clin Oncol 27(13):2231\u20132237. doi: 10.1200\/JCO.2008.20.0238","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"22","key":"2147_CR24","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1200\/JCO.2010.28.1386","volume":"28","author":"HL Kindler","year":"2010","unstructured":"Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O\u2019Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol: Off J Am Soc Clin Oncol 28(22):3617\u20133622. doi: 10.1200\/JCO.2010.28.1386","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"5","key":"2147_CR25","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.2353\/ajpath.2010.090899","volume":"177","author":"Z Xu","year":"2010","unstructured":"Xu Z, Vonlaufen A, Phillips PA, Fiala-Beer E, Zhang X, Yang L, Biankin AV, Goldstein D, Pirola RC, Wilson JS, Apte MV (2010) Role of pancreatic stellate cells in pancreatic cancer metastasis. Am J Pathol 177(5):2585\u20132596. doi: 10.2353\/ajpath.2010.090899","journal-title":"Am J Pathol"},{"issue":"19","key":"2147_CR26","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1158\/1078-0432.CCR-08-0291","volume":"14","author":"JM Bailey","year":"2008","unstructured":"Bailey JM, Swanson BJ, Hamada T, Eggers JP, Singh PK, Caffery T, Ouellette MM, Hollingsworth MA (2008) Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 14(19):5995\u20136004. doi: 10.1158\/1078-0432.CCR-08-0291","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"5933","key":"2147_CR27","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1126\/science.1171362","volume":"324","author":"KP Olive","year":"2009","unstructured":"Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Ruckert F, Grutzmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324(5933):1457\u20131461. doi: 10.1126\/science.1171362","journal-title":"Science"},{"issue":"1\u20132","key":"2147_CR28","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cell.2011.11.025","volume":"148","author":"AD Rhim","year":"2012","unstructured":"Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, Leach SD, Stanger BZ (2012) EMT and dissemination precede pancreatic tumor formation. Cell 148(1\u20132):349\u2013361. doi: 10.1016\/j.cell.2011.11.025","journal-title":"Cell"},{"issue":"6024","key":"2147_CR29","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","volume":"331","author":"GL Beatty","year":"2011","unstructured":"Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O\u2019Dwyer PJ, Vonderheide RH (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331(6024):1612\u20131616. doi: 10.1126\/science.1198443","journal-title":"Science"},{"issue":"3","key":"2147_CR30","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","volume":"21","author":"PP Provenzano","year":"2012","unstructured":"Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR (2012) Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21(3):418\u2013429. doi: 10.1016\/j.ccr.2012.01.007","journal-title":"Cancer Cell"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2147-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2147-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2147-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T11:30:13Z","timestamp":1644665413000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2147-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,27]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["2147"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2147-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,27]]}}}